JETEMA, Co (216080) Fair Value & Analysis
Healthcare · KR · Market cap 157B KRW
Fair value as of: Jul 22, 2026
From 4 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 1,723 KRW to 1,660 KRW (−3.6%) since Jul 7, 2026. Share price +0.2% over the past month.
Below-average quality, and screening another 64% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,825 KRW). The favourable scenario is already priced in.
- Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (496.00 KRW to 2,825 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 4,140 KRW – 20,100 KRW · fair‑value band 496.00 KRW – 2,825 KRW · the 4,550 KRW price screens above the 1,660 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
JETEMA, Co (216080) currently trades at 4,550 KRW, while our model-based Fair Value estimate is 1,660 KRW, implying the stock looks roughly 63.5% overvalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, JETEMA, Co generated revenue of 77.1B KRW at a net margin of -6.6%. Revenue grew 1.1% year over year. It earns a return on equity of -8.2%. Net debt stands at 112B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 496.00 KRW (bear case) to 2,825 KRW (bull case); at 4,550 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -64%, 216080 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Asset-Based (1,179 KRW) versus Multiples (529.82 KRW). Highest evidence: EV/EBITDA (54).
Notify me when 216080 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 27 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names.
Full company description
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks. JETEMA, Co., Ltd. was founded in 2009 and is headquartered in Wonju-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JETEMA, Co reported revenue of 76.9B KRW in FY2025 versus 33.2B KRW in FY2021, a compound +23.3%/yr. Reported net income was −6.6B KRW in FY2025.
216080 screens 64% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare JETEMA, Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is JETEMA, Co (216080) overvalued or undervalued?
What is the fair value of 216080?
What is the quality score of 216080?
What is the revenue of JETEMA, Co (216080)?
What is the net profit margin of 216080?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track JETEMA, Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.